We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 2.06% | 39.70 | 39.15 | 39.80 | 39.35 | 38.85 | 39.05 | 315,724 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 3.1M | -6.51M | -0.0217 | -18.04 | 117.73M |
TIDMFUM
RNS Number : 5668Z
Futura Medical PLC
15 January 2024
15 January 2024
Futura Medical plc
("Futura" or the "Company")
Futura Medical extends collaboration with Cooper Consumer Health
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products , today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health ("Cooper"), a leading European independent self-care organisation, for the rights to commercialise Eroxon (R), the Company's topical, gel-based Erectile Dysfunction ("ED") treatment, throughout the European Economic Area, United Kingdom and Switzerland.
The extension builds on an initial agreement signed in May 2022 for the exclusive rights to commercialise Eroxon in these territories for an initial five-year period. The terms of the agreement are otherwise unchanged with Futura remaining the Legal Manufacturer(1) and responsible for the supply of Eroxon through its third-party contract manufacturers. Futura looks forward to continuing to grow its relationship with Cooper.
Eroxon has been approved as the first pan-European topical treatment for ED available without prescription. Initial launches commenced in March 2023 in the UK and Belgium, with further launches across Europe during 2024, including the key markets of Italy, Spain, France and Germany.
James Barder, Chief Executive Officer of Futura Medical said : "The award-winning launch of Eroxon was a key milestone in our partnership with Cooper and the success of our collaboration makes this extension an easy decision for both parties. We are committed to providing treatment to those suffering from ED and as such we continue the commercial roll-out of Eroxon across the world."
Bart Meermans, President of Cooper Consumer Health said: "Cooper's ambition is to become a leading European consumer healthcare platform. Eroxon is an exciting new innovation for the erectile dysfunction market and we look forward to working closely with Futura with the continuing launches of Eroxon across our markets."
(1) Legal manufacturer means the organisation responsible for the design, manufacture, packaging and labelling of a device before it is placed on the market under that organisation's own name, regardless of whether these operations are carried out by that organisation or on its behalf by a third party contract manufacturer.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin / Jonathan Edwards / Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative sexual health products based on its proprietary, transdermal DermaSys(R) technology. Each DermaSys(R) formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel treatment for erectile dysfunction ("ED") through a unique evaporative mode of action and is sold in Europe and the UK under the brand name Eroxon(R). Futura has conducted two Phase 3 studies using MED3000 in ED; the FM57 study which enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura to be granted US marketing authorisation. Both studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for an 'Over the Counter' classification.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
About Cooper Consumer Health Group
Cooper Consumer Health Group ("Cooper") is the largest independent selfcare organization in Europe that is active in the OTC consumer healthcare market with the development, manufacturing, selling and marketing of selfcare products (e.g. medicines, medical devices, cosmetics, biocides and food supplements) under its own or licensed brands.
The ambition of the group is to offer selfcare solutions to everyone based on a European brands portfolio. Cooper has proven its capacity to integrate new activities and aggregate talents by capitalising on the
strengths and the structure of its group. www.cooperconsumerhealth.eu
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCBBGDBXGBDGSD
(END) Dow Jones Newswires
January 15, 2024 02:00 ET (07:00 GMT)
1 Year Futura Medical Chart |
1 Month Futura Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions